Virus-like Particle & Nano-Particle Vaccines (VLPNPV) 2026

Virus-like Particle & Nano-Particle Vaccines (VLPNPV) 2026 is organized by MEDICONmm and will be held from Oct 06 - 08, 2026 at Inselspital, Bern, Switzerland.

Description:
Virus-like particles are supra-molecular assemblages incorporating key immunologic features of viruses which include repetitive surfaces, particulate structures with potential for induction of innate immunity through activation of pathogen-associated molecular-pattern recognition receptors.

They carry no replicative genetic information and can be produced in heterologous expression systems at large scale. Virus-like particles thus represent a safe and effective vaccine platform with potential to induce potent B- and T-cell responses.

In addition to being effective vaccines against the corresponding viruses from which they are derived, virus-like particles can also be used to present foreign epitopes to the immune system. This can be achieved by genetic fusion or chemical conjugation. This technological innovation has greatly broadened the scope of their use, from immunizing against microbial pathogens to immunotherapy for chronic diseases.

Towards this end, virus-like particles have been used to induce auto-antibodies to disease-associated self-molecules involved in chronic diseases, such as hypertension and Alzheimer’s disease. The recognition of the potent immunogenicity and commercial potential for virus-like particles has greatly accelerated research and development activities. During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development.

VLPNPV 2026 is the seventh meeting in this new series, the first being held in Cannes in 2012, for international researchers working on Virus-Like Particles (VLPs) the multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, and Nano-Particles potentially yielding safer and cheaper vaccine candidates.

A small number of prophylactic VLP-based vaccines are currently commercialized worldwide: GlaxoSmithKline’s Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.’s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests.

This meeting will focus on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production will be important for process control, monitorization and optimization. VLP-based and NP-based vaccines updates will be presented with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.

The success of the COVID-19 mRNA vaccines, nanoscale platforms are promising delivery vectors for effective and safe vaccines. Synthetic nanoscale platforms, including liposomes and inorganic nanoparticles and microparticles, have many advantages in the vaccine market, but often require multiple doses and addition of artificial adjuvants, such as aluminium hydroxide. Biologically derived nanoparticles, on the other hand, contain native pathogen-associated molecular patterns (PAMPs), which can reduce the need for artificial adjuvants. VLPNPV 2026 will focus on the emphasising these developments in the VLP and NPV topics.

Conference Scope:

• Virus-Like Particle Vaccines
• VLP Vaccine Manufacturing
• Nano-Particles and Nano-Particulate Vaccines
• VLP Platforms as Delivery Systems for Therapeutics, Imaging and Antigen Presentation
• Structure (non-enveloped, enveloped and synthetic)
• Formulation and Stability of VLP and Nano-Particulate Vaccines and Adjuvants
• Delivery Systems (including Microneedles)
• VLP Expression Systems (Baculovirus, Cell Culture, Yeast, Plants)
• Safety and Regulatory Issues (regulation of expression systems)
• HepB
• HPV
• Influenza
• Developing VLP Candidates
• Clinical Trials Updates
• ISCOMs & ISCOMATRIX
• Chitosan Particles
• Liposomes
• VLPs as Protein Delivery Systems
• VLPs for Drug Delivery
• Novel Applications (eg Cell-Free Synthesis)
• Nanotechnology Approaches (Non-Conventional VLPs)
• Particulate-Based Vaccines
• mRNA Vaccines